The partnership combines AKBA’s industry knowledge and product expertise with PeptiSystems’ next-generation synthesizers.

Forge Biologics has entered an AAV development and manufacturing agreement to help advance Fractyl Health’s Rejuva platform.

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.